GILMAN STEVEN C — SEC Form 4 filings
SEC reporting owner CIK 1379970. 9 Form 4 filings on record with FilingPulse; latest filed 2025-06-30.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-05-03 to 2025-06-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 4 filings — 22,500 shares, $985,195 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 5,834 shares @ $45.54 ($265,680) in Vericel Corp, filed 2024-09-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vericel Corp (VCEL) | Director | 5 | — | 4 legs · 22,500 sh · $985,195 | 12 |
| Akebia Therapeutics, Inc. (AKBA) | Director | 2 | — | — | 4 |
| SCYNEXIS INC (SCYX) | Director | 2 | — | — | 4 |
Form 4 filings — GILMAN STEVEN C
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-06-30 | 4 | SCYNEXIS INC (SCYX) | Grant/award (A): 23,000 @ $0 · Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Akebia Therapeutics, Inc. (AKBA) | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2024-10-18 | 4 | Vericel Corp (VCEL) | Option exercise (M): 5,833 @ $13.05 · Sale (S): 5,833 @ $41.36 · Option exercise (M): 5,833 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Vericel Corp (VCEL) | Option exercise (M): 5,833 @ $13.05 · Sale (S): 5,833 @ $40.35 · Option exercise (M): 5,833 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | Vericel Corp (VCEL) | Option exercise (M): 5,834 @ $13.05 · Sale (S): 5,834 @ $45.54 · Option exercise (M): 5,834 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Vericel Corp (VCEL) | Option exercise (M): 5,000 @ $3.74 · Sale (S): 5,000 @ $48.58 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | SCYNEXIS INC (SCYX) | Grant/award (A): 23,000 @ $0 · Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Akebia Therapeutics, Inc. (AKBA) | Grant/award (A): 30,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Vericel Corp (VCEL) | Option exercise (M): 3,200 · Option exercise (M): 3,200 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 · Grant/award (A): 3,200 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1379970 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →